Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Net Cash Flow: 2011-2025

Historic Net Cash Flow for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$80.7 million.

  • Abeona Therapeutics' Net Cash Flow fell 331.29% to -$80.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.2 million, marking a year-over-year increase of 509.75%. This contributed to the annual value of $8.9 million for FY2024, which is 3370.31% up from last year.
  • As of Q3 2025, Abeona Therapeutics' Net Cash Flow stood at -$80.7 million, which was down 154.64% from $147.6 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Net Cash Flow peaked at $147.6 million during Q2 2025, and registered a low of -$80.7 million during Q3 2025.
  • For the 3-year period, Abeona Therapeutics' Net Cash Flow averaged around $6.2 million, with its median value being $1.5 million (2023).
  • Over the last 5 years, Abeona Therapeutics' Net Cash Flow had its largest YoY gain of 991.78% in 2024, and its largest YoY loss of 1,135.96% in 2024.
  • Over the past 5 years, Abeona Therapeutics' Net Cash Flow (Quarterly) stood at -$5.9 million in 2021, then surged by 158.78% to $3.5 million in 2022, then spiked by 180.17% to $9.8 million in 2023, then dropped by 21.82% to $7.6 million in 2024, then tumbled by 331.29% to -$80.7 million in 2025.
  • Its last three reported values are -$80.7 million in Q3 2025, $147.6 million for Q2 2025, and -$7.4 million during Q1 2025.